[1]罗圣丽,李伟华,陈 琼.德谷门冬双胰岛素注射液联合阿卡波糖治疗2型糖尿病的安全性研究[J].医学信息,2024,37(22):70-73.[doi:10.3969/j.issn.1006-1959.2024.22.017]
　LUO Shengli,LI Weihua,CHEN Qiong.Study on the Safety of Insulin Degludec and Insulin Aspart Injection Combined with Acarbose in the Treatment of Type 2 Diabetes Mellitus[J].Journal of Medical Information,2024,37(22):70-73.[doi:10.3969/j.issn.1006-1959.2024.22.017]
点击复制

德谷门冬双胰岛素注射液联合阿卡波糖治疗2型糖尿病的安全性研究()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年22期
页码:
70-73
栏目:
论著
出版日期:
2024-11-15

文章信息/Info

Title:
Study on the Safety of Insulin Degludec and Insulin Aspart Injection Combined with Acarbose in the Treatment of Type 2 Diabetes Mellitus
文章编号:
1006-1959（2024）22-0070-04
作者:
罗圣丽; 李伟华; 陈 琼
信丰县人民医院药剂科，江西 信丰 341600
Author(s):
LUO Shengli; LI Weihua; CHEN Qiong
Pharmacy Department of Xinfeng County People’s Hospital,Xinfeng 341600,Jiangxi,China
关键词:
德谷门冬双胰岛素注射液; 阿卡波糖; 2型糖尿病; 安全性
Keywords:
Insulin degludec and insulin aspart injection; Acarbose; Type 2 diabetes mellitus; Safety
分类号:
R587
DOI:
10.3969/j.issn.1006-1959.2024.22.017
摘要:
目的 研究德谷门冬双胰岛素注射液联合阿卡波糖治疗2型糖尿病的安全性与有效性。方法 选取2022年5月-2023年7月在我院诊治的72例2型糖尿病患者为研究对象，采用随机数字表法分为常规组（36例）和试验组（36例），常规组采用德谷门冬双胰岛素注射液治疗，试验组在常规组基础上应用阿卡波糖治疗。比较两组临床疗效、血糖指标[糖化血红蛋白（HbA1c）、空腹血糖（FPG）]、血脂指标[甘油三酯（TG）、总胆固醇（TC）]、血清摄食抑制因子1（Nesfatin-1）、脂联素（ADP）水平及不良反应发生率。结果 试验组治疗总有效率（97.22%）高于常规组（83.33%）（P＜0.05）；两组治疗后HbA1c、FPG均低于治疗前，且试验组低于常规组（P＜0.05）；两组治疗后TG、TC均低于治疗前，且试验组低于常规组（P＜0.05）；两组治疗后Nesfatin-1均低于治疗前，ADP均高于治疗前，且试验组Nesfatin-1低于常规组，ADP高于常规组（P＜0.05）；试验组不良反应发生率（8.33%）低于常规组（19.44%）（P＜0.05）。结论 2型糖尿病患者采用德谷门冬双胰岛素注射液和阿卡波糖联合可提高总有效率，改善血糖于血脂指标，降低Nesfatin-1水平，提升ADP水平，是一种安全性、有效的联合治疗方案。
Abstract:
Objective To study the safety and efficacy of insulin degludec and insulin aspart injection combined with acarbose in the treatment of type 2 diabetes mellitus.Methods Totally 72 type 2 diabetes mellitus patients who were diagnosed and treated in our hospital from May 2022 to July 2023 were selected as the research objects. Using the random number table method, patients were divided into routine group (n=36) and test group (n=36). In the routine group, patients were treated with insulin degludec and insulin aspart injection, while in the test group, patients were treated with acarbose on the basis of the routine group. The clinical efficacy, blood glucose indexes [glycosylated hemoglobin (HbA1c), fasting blood glucose (FPG)], blood lipid indexes [triglyceride (TG), total cholesterol (TC)], serum feeding inhibitor 1 (Nesfatin-1), adiponectin (ADP) levels and incidence of adverse reactions were compared between the two groups.Results Compared with the routine group (83.33%), the total effective rate of treatment in the test group (97.22%) was higher (P<0.05). After treatment, HbA1c and FPG in the two groups were lower than those before treatment, and compared with the routine group, those in the test group were lower (P<0.05). After treatment, TG and TC in the two groups were lower than those before treatment, and compared with the routine group, those in the test group were lower (P<0.05). After treatment, Nesfatin-1 in the two groups was lower than that before treatment, ADP was higher than that before treatment, and compared with the routine group, Nesfatin-1 in the test group was lower, ADP was higher (P<0.05). Compared with the routine group (19.44%), the incidence of adverse reactions in the test group (8.33%) was lower (P<0.05).Conclusion The combination of insulin degludec and insulin aspart injection combined with acarbose in patients with type 2 diabetes mellitus can improve the total effective rate, improve blood glucose and blood lipid indexes, reduce the level of nesfatin-1, and increase the level of ADP. It is a safe and effective combination therapy.

参考文献/References:

[1]刘影.德谷胰岛素与甘精胰岛素治疗口服降糖药血糖控制不佳2型糖尿病患者的效果比较[J].中国实用乡村医生杂志,2022,29(1):44-46.[2]张燕梅.地特胰岛素与二甲双胍联合治疗2型糖尿病的药理分析及疗效观察[J].基层医学论坛,2021,25(34):4999-5001.[3]李萍,沈焕玲,徐谷根,等.德谷门冬双胰岛素优化伴有多系统并发症的2型糖尿病患者的血糖及葡萄糖在目标范围内时间一例及文献复习[J].中华糖尿病杂志,2021,13(1):4-7.[4]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4):292-344.[5]倪冰玉,魏国旭,朱贺,等.德谷胰岛素在中国2型糖尿病起始胰岛素治疗中的短期成本-效用分析[J].临床药物治疗杂志,2019,17(7):8-11,22.[6]刘佳,崔旭红,王丽艳,等.预混胰岛素联合二甲双胍对新诊断2型糖尿病患者胰岛功能恢复的影响[J].河北医学,2019,25(1):18-22.[7]陶立波,王芳旭.医保准入后德谷门冬双胰岛素对比甘精胰岛素治疗口服降糖药控制不佳的中国2型糖尿病患者的成本-效果[J].药品评价,2021,18(4):193-196.[8]田莉.门冬胰岛素联合德谷胰岛素或甘精胰岛素强化治疗初诊2型糖尿病疗效观察[J].甘肃医药,2019,38(9):797-798.[9]史莎莎,宋勇刚,吕淑云.德谷门冬双胰岛素优化治疗预混胰岛素控制不佳的2型糖尿病一例[J].中华糖尿病杂志,2021,13(1):36-38.[10]石慧敏,丘军,贾冬梅,等.门冬胰岛素30不同注射次数对老年2 型糖尿病患者临床疗效的比较[J].中国糖尿病杂志,2017,25(5):403-406.[11]李蕊,金晓娜,张党锋.维格列汀联合门冬胰岛素30注射液对肥胖型2型糖尿病患者胰岛 β细胞功能及血清糖化血红蛋白水平的影响[J].武警医学,2019,30(6):499-502.[12]庞静,李霞,徐杰,等.西格列汀联合阿卡波糖治疗Ⅱ型糖尿病对脂代谢紊乱与胰岛素抵抗的影响[J].西部医学,2017,29(10):1373-1376.[13]李冬玲,李远,陈燕铭.甘精胰岛素联合格列美脲和阿卡波糖治疗磺脲类药物治疗失效的2型糖尿病的疗效观察[J].现代药物与临床,2017,32(3):423-427.[14]李静静,方枝俏,奚超,等.阿卡波糖联合甘精胰岛素对 2 型糖尿病患者胰岛功能、血脂水平的影响及安全性[J].临床误诊误治,2022,35(4):36-39,45.[15]陈鹤鸣,张晓军,陈浩,等.阿卡波糖联合西格列汀对2型糖尿病患者糖脂代谢紊乱及慢性炎性反应的作用[J].疑难病杂志,2022,21(3):287-292.[16]Kalra S,Atkin S,Cervera A,et al.Multinational consensus:insulin initiation with insulin Degludec/Aspart(IDeg Asp)[J].AdvTher,2018,35:928-936.[17]甘明珠.甘精胰岛素联合阿卡波糖对绝经期糖尿病患者糖脂代谢、空腹C肽、血管内皮功能及炎症因子的影响[J].海军医学杂志,2020,41(5):552-556,560.[18]石玉英.甘精胰岛素联合阿卡波糖治疗2型糖尿病疗效观察[J].中国药物与临床,2020,20(11):1829-1830.[19]彭静,张文,栾家杰.阿卡波糖联合格列吡嗪治疗2型糖尿病临床疗效的系统评价[J].解放军医药杂志,2020,32(5):53-56.[20]邱杰芳.甘精胰岛素及门冬胰岛素30联合二甲双胍治疗2型糖尿病有效性和安全性比较[J].内蒙古医学杂志,2021,53(9):1093-1094.

相似文献/References:

[1]吴圆琴.甘精胰岛素联合阿卡波糖治疗2型糖尿病的效果及对胰岛素抵抗的影响[J].医学信息,2023,36(19):148.[doi:10.3969/j.issn.1006-1959.2023.19.033]
　WU Yuan-qin.Effect of Insulin Glargine Combined with Acarbose in the Treatment of Type 2 Diabetes Mellitus and its Effect on Insulin Resistance[J].Journal of Medical Information,2023,36(22):148.[doi:10.3969/j.issn.1006-1959.2023.19.033]

更新日期/Last Update: 1900-01-01